Product Launch (Blog)

Apr, 25 2024

Transforming Respiratory Health: Top Players Leading the Charge in Viral Infections Treatment

The viral respiratory infections treatment market encompasses the development and distribution of antiviral medications targeting viruses such as influenza and respiratory syncytial virus (RSV), aiming to alleviate symptoms and reduce complications. It includes the production of vaccines for prevention, aiding in outbreak control and transmission reduction. Diagnostic tools for rapid and accurate identification of these infections play a crucial role in guiding treatment decisions and implementing public health measures. Advancements in this market contribute to improved patient outcomes and public health by effectively managing viral respiratory diseases, thus mitigating their impact on individuals and communities.

Global Viral Respiratory Infections Treatment Market size is valued at USD 57,365.34 million in 2023 and is projected to reach USD 108,207.05 million by 2031, with a CAGR of 8.5% during the forecast period of 2024-2031.

To know more, visit

Below are the Top Viral Respiratory Infections Treatment Companies with a Significant Market Share:




Product Portfolio

Sales Geographical Coverage



Pfizer Inc.

A leading pharmaceutical company with a significant presence in the viral respiratory infections treatment market, offering vaccines and antiviral medications such as Tamiflu (oseltamivir) for influenza.

  • Pfizer-BioNTech COVID-19 Vaccine (also known as BNT162b2)
  • ABRYSVO Cancer-related

North America, South America, Asia-Pacific, Europe, and Middle east and Africa

In September 2023, Pfizer Inc. announced that after voting in favor of ABRYSVO [Respiratory Syncytial Virus Vaccine], the company's bivalent RSV prefusion F (RSVpreF) vaccine, as a maternal immunization, the Advisory Committee on Immunisation Practises (ACIP) of the U.S. Centres for Disease Control and Prevention (CDC) recommended that the company expand its portfolio of respiratory vaccines. For the first time ever, eligible people can now receive Pfizer immunisations in the autumn to help prevent pneumococcal pneumonia, COVID-19, and RSV. This helped the company to expand its business.


GSK plc.

Known for its expertise in vaccines and antiviral drugs, GSK has a strong portfolio in respiratory treatments, including vaccines for influenza and innovative therapies for respiratory syncytial virus (RSV) and COVID-19.

  • Xevudy
  • Arexvy
  • Nucala


North America, South America, Asia-Pacific, Europe, and Middle east and Africa

In May 2023, GSK plc. announced that the U.S. Food and Drug Administration (FDA) authorized Arexvy, an adjuvanted respiratory syncytial virus vaccine, for the prevention of Lower Respiratory Tract Disease (LRTD) in people 60 years of age and older.  This is the first RSV vaccine for the elderly that has been authorized globally.


Gilead Sciences, Inc.

Gilead is recognized for its antiviral drugs, notably remdesivir, which gained emergency use authorization for treating COVID-19. The company continues to explore new avenues in viral respiratory infection treatments.

  • Veklury (remdesivir)
  • Cayston

North America, South America, Asia-Pacific, Europe, and Middle east and Africa

The FDA's expansion of indication for Gilead's Vemlidy to treat chronic HBV infection in pediatric patients as young as six strengthens Gilead's position in the viral respiratory infections treatment market. Gilead Sciences, Inc. is a key player in this market, and this expansion broadens its reach by addressing a previously unmet medical need in pediatric patients. With Vemlidy now approved for a younger patient demographic, Gilead stands to capture a larger share of the market for HBV treatment, further solidifying its presence in the viral respiratory infections treatment landscape.


F. Hoffmann-La Roche Ltd.

Roche is prominent in the development of diagnostic tests and antiviral medications, such as oseltamivir (Tamiflu), for influenza. It also contributes to research and development efforts in emerging viral respiratory infections.

  • Copegus (ribavarin)
  • Actemra/RoActemra (tocilizumab)
  • Rocephin (ceftriaxone)
  • Tamiflu (oseltamivir)
  • Xofluza (baloxavir marboxil)


North America, South America, Asia-Pacific, Europe, and Middle east and Africa

In May 2023, Hasten Biopharmaceutic Co., Ltd announced that the long-acting, broad-spectrum cephalosporin antibiotic Rocephin's commercial rights in China had been bought from the international healthcare business F.Hoffmann La-Roche Ltd in Switzerland. There was a transition phase between Hasten and Roche after the purchase closed earlier this year. Hasten obtained Roche's rights to commercialize Rocephin in China's mainland as per the terms of the arrangement, along with some intellectual property, such as trademarks, and the authorization to promote the product. This acquisition helped the company to market its drug medications and expand its product line.


Johnson & Johnson Services, Inc.

J&J is involved in the development of vaccines and antiviral therapies, including efforts against COVID-19. With its broad healthcare portfolio, the company plays a vital role in combating viral respiratory infections through both prevention and treatment measures.

  • COVID 19 Vaccine


North America, South America, Asia-Pacific, Europe, and Middle east and Africa

In February 2021, Johnson & Johnson Services, Inc. reported that the single-dose COVID-19 vaccine, created by Johnson & Johnson's Janssen Pharmaceutical Companies, has received an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) to prevent COVID-19 in people 18 years of age and older. The EUA's provisions permit vaccination usage while additional information is being obtained. Later in 2021, the company intends to submit a Biologics Licence Application (BLA) to the FDA.


The global viral respiratory infections treatment market is poised for significant growth, driven by advancements in antiviral medications, vaccines, and diagnostic tools. Key players such as Pfizer, GSK, Gilead Sciences, Roche, and Johnson & Johnson are at the forefront, offering diverse portfolios to address various respiratory viruses, including influenza, RSV, and COVID-19. With increasing investment in research and development, coupled with expanding geographical reach, these companies are pivotal in shaping the landscape of viral respiratory infection management, ultimately contributing to improved patient outcomes and public health worldwide.

Client Testimonials